본 연구에서 NUP62의 발현 억제는 방사선 저항성 육종에서 BCL-2발현을 억제하여 세포 자멸사를 증가시키고, 세포 증식은 억제 하며, DNA 2중 나선 손상 기전에 영향을 주어 방사선 민감제 타겟으로 서 잠재적 가능성을 확인하는 예비 결과를 in-vitro에서 얻었다. 본 연 구의 발견을 바탕으로 NUP62를 기반으로 하는 후속 실험실 및 임상 연 구의 기초 근거가 될 수 있을 것으로 기대되며, 이는 장기적으로 효과적 인 siRNA 전달체의 개발이 진행된다면 수술적 절제가 불가능한 육종 환자의 치료 성적 향상에도 기여할 수 있을 것으로 기대된다.
40
참고문헌
1. Fletcher CDM, World Health Organization., International Agency for Research on Cancer. WHO classification of tumours of soft tissue and bone. 4th ed. Lyon: IARC Press; 2013.
2. Kang S, Kim HS, Kim S, Kim W, Han I. Post-metastasis survival in extremity soft tissue sarcoma: a recursive partitioning analysis of prognostic factors. European journal of cancer. 2014;50(9):1649-1656.
3. Hoang NT, Acevedo LA, Mann MJ, Tolani B. A review of soft-tissue sarcomas: translation of biological advances into treatment measures.
Cancer Manag Res. 2018;10:1089-1114.
4. Kim W, Han I, Lee JS, Cho HS, Park JW, Kim HS. Postmetastasis survival in high-grade extremity osteosarcoma: A retrospective analysis of prognostic factors in 126 patients. Journal of surgical oncology. 2018.
5. de Silva CM, Reid R. Gastrointestinal stromal tumors (GIST): C-kit mutations, CD117 expression, differential diagnosis and targeted cancer therapy with Imatinib. Pathology oncology research : POR.
2003;9(1):13-19.
6. Pisters PW, Ballo MT, Patel SR. Preoperative chemoradiation treatment strategies for localized sarcoma. Annals of surgical oncology.
2002;9(6):535-542.
7. Murphy JD, Lucas DR, Somnay YR, Hamstra DA, Ray ME.
Gemcitabine-mediated radiosensitization of human soft tissue sarcoma.
41
Translational oncology. 2008;1(1):50-56.
8. Murphy JD, Spalding AC, Somnay YR, Markwart S, Ray ME, Hamstra DA. Inhibition of mTOR radiosensitizes soft tissue sarcoma and tumor vasculature. Clinical cancer research : an official journal of the American Association for Cancer Research. 2009;15(2):589-596.
9. Eckert F, Matuschek C, Mueller AC, et al. Definitive radiotherapy and single-agent radiosensitizing ifosfamide in patients with localized, irresectable soft tissue sarcoma: a retrospective analysis. Radiation oncology. 2010;5:55.
10. Song EJ, Ashcraft KA, Lowery CD, et al. Investigating a chimeric anti- mouse PDGFRalpha antibody as a radiosensitizer in primary mouse sarcomas. EBioMedicine. 2019;40:224-230.
11. Duheron V, Nilles N, Pecenko S, Martinelli V, Fahrenkrog B.
Localisation of Nup153 and SENP1 to nuclear pore complexes is required for 53BP1-mediated DNA double-strand break repair. J Cell Sci. 2017;130(14):2306-2316.
12. Mackay DR, Howa AC, Werner TL, Ullman KS. Nup153 and Nup50 promote recruitment of 53BP1 to DNA repair foci by antagonizing BRCA1-dependent events. J Cell Sci. 2017;130(19):3347-3359.
13. Rodriguez-Berriguete G, Granata G, Puliyadi R, et al. Nucleoporin 54 contributes to homologous recombination repair and post-replicative DNA integrity. Nucleic acids research. 2018;46(15):7731-7746.
14. Hashizume C, Moyori A, Kobayashi A, Yamakoshi N, Endo A, Wong
42
RW. Nucleoporin Nup62 maintains centrosome homeostasis. Cell cycle.
2013;12(24):3804-3816.
15. Borlido J, D'Angelo MA. Nup62: a novel regulator of centrosome integrity and function. Cell cycle. 2014;13(1):14.
16. Wu Z, Jin Z, Zhang X, et al. Nup62, associated with spindle microtubule rather than spindle matrix, is involved in chromosome alignment and spindle assembly during mitosis. Cell Biol Int.
2016;40(9):968-975.
17. Kehr S, Haydn T, Bierbrauer A, Irmer B, Vogler M, Fulda S. Targeting BCL-2 proteins in pediatric cancer: Dual inhibition of BCL-XL and MCL-1 leads to rapid induction of intrinsic apoptosis. Cancer letters.
2020;482:19-32.
18. Lee EF, Harris TJ, Tran S, et al. BCL-XL and MCL-1 are the key BCL- 2 family proteins in melanoma cell survival. Cell Death Dis.
2019;10(5):342.
19. Rothkamm K, Horn S. gamma-H2AX as protein biomarker for radiation exposure. Ann Ist Super Sanita. 2009;45(3):265-271.
20. Mah LJ, El-Osta A, Karagiannis TC. gammaH2AX: a sensitive molecular marker of DNA damage and repair. Leukemia.
2010;24(4):679-686.
21. Wang H, Mu X, He H, Zhang XD. Cancer Radiosensitizers. Trends Pharmacol Sci. 2018;39(1):24-48.
22. Kim BH, Kim YJ, Kim MH, et al. Identification of FES as a Novel
43
Radiosensitizing Target in Human Cancers. Clinical cancer research : an official journal of the American Association for Cancer Research.
2020;26(1):265-273.
23. Wang J, Lu Z, Wientjes MG, Au JL. Delivery of siRNA therapeutics:
barriers and carriers. AAPS J. 2010;12(4):492-503.
24. Karunaratne DN, Jafari M, Ranatunga RJ, Siriwardhana A. Natural Carriers for siRNA Delivery. Curr Pharm Des. 2015;21(31):4529-4540.
25. Liu H, Chang H, Lv J, et al. Screening of efficient siRNA carriers in a library of surface-engineered dendrimers. Sci Rep. 2016;6:25069.
26. Choi CKK, Zhang L, Choi CHJ. Efficient siRNA delivery with non- cationic carriers. Nat Biomed Eng. 2018;2(5):275-276.
44
참고 그림
Supplementary figure 1. 활액막 육종 세포주 (SW982, HSSY2), 섬유아 세 포주 (HDF)에서 시행한 CCK-8 assay. A, 활액막 육종에서 과발현 되는 TLE-1에 대한 siRNA를 이용하여 발현 억제 시킨 후 Doxorubicin 처리하고 CCK-8 assay시행하였을 때 control에 비하여 세포사가 증가함을 확인. B, NUP62를 발현 억제 시킨후 Doxorubicin 처리하였을 때 대조군에 비하여 항 암 민감도 증가 효과가 크지 않음.
45
Supplementary figure 1C. SW982에서 NUP62와 TLE1에 대한 siRNA를 이 용하여 발현 억제 후, 방사선 조사하고 colony formation assay 결과.
NUP62의 경우 대조군에 비하여 세포 증식이 떨어짐을 확인할 수 있으나, TLE1의 경우 대조군에 비하여 방사선 조사 후 세포 증식이 감소하지 않음을 보여줌.
46